

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

PROPOSED ACQUISITION OF 15% EQUITY INTEREST IN TIANJIN PHARMACEUTICAL GROUP FINANCE CO., LTD. (天津医药集团财务有限公司)

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) and together with its subsidiaries, the “Group”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the announcement dated 11 September 2023 made by the Company on the resolution passed at the 6th Board meeting for the financial year ending 31 December 2023 (the “**FY2023 6th Board Meeting**”) in relation to the Company’s proposed acquisition of 15% equity interest in Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) (“**TPGF**”) through a public bidding (公开摘牌) process (the “**Proposed Acquisition**”) (the “**Announcement**”).

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcement.

1. INTRODUCTION

1.1 On 28 August 2023, the Tianjin Property Rights Exchange (天津产权交易中心) (the “**TPRE**”) released an announcement that Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生制药股份有限公司) (“**Lisheng Pharmaceutical**”) initiated a public listing-for-sale (公开挂牌转让) process on the TPRE for a period from 28 August 2023 to 22 September 2023 to dispose all of its 15% equity interest in TPGF (the “**Sale Equity**”), with an initial bidding price of RMB87,823,860 (the “**Initial Bidding Price**”). The Company proposes to participate in the bidding for the Sale Equity at the Initial Bidding Price, representing approximately 1.35% of the Group’s latest audited net tangible assets (“**NTA**”) of RMB6,493,593,000 as at 31 December 2022. The Company intends to finance the Proposed Acquisition through its internal resources. Shareholders and/or potential investors should note that, if a competitive bidding process occurs, the final transaction price for the Sale Equity will be determined based on the bidding results.

If and when the Proposed Acquisition is completed, the Company’s shareholding in TPGF will increase from 15% to 30%.

1.2 As at the date of this announcement, the Company’s controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“**TPH**”) is deemed to have an interest of approximately 50.93% in Lisheng Pharmaceutical. Accordingly, Lisheng Pharmaceutical is an associate (as defined under the Listing Manual) of TPH and therefore, Lisheng Pharmaceutical is regarded as an interested person of the Company for the purposes of Chapter 9 of the Listing Manual (the “**Listing Manual**”) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”), and the Proposed Acquisition constitutes an interested person transaction under the Listing Manual.

- 1.3 As at the date of this announcement, the Board comprises nine (9) directors (the “**Directors**”), of which, each of Mr. Guo Min, Ms. Zhang Mingrui and Ms. Wao Weiwen is a key management personnel in TPH (the “**Interested Directors**”). Since TPH is regarded as an interested person of the Company for the purposes of Chapter 9 of the Listing Manual, the Interested Directors have abstained from voting at the FY2023 6th Board Meeting in respect of the resolution approving the Proposed Acquisition, and the remaining six (6) directors (including all the three (3) independent directors of the Company for the time being (the “**Independent Directors**”)) have approved the Proposed Acquisition.

The Proposed Acquisition does not constitute material asset restructuring pursuant to the laws of the People’s Republic of China (the “**PRC**”), and it is not required to submit the Proposed Acquisition for shareholders’ approval.

As further elaborated in paragraphs 5 and 6 of this announcement, the Proposed Acquisition constitutes a “non-discloseable transaction” pursuant to Rule 1008 of the Listing Manual and an interested person transaction which is not subject to the disclosure requirements under Chapter 9 of the Listing Manual.

For the avoidance of doubt, the Company is making this announcement in accordance with Rules 217 and 703 of the Listing Manual.

2. OVERVIEW

2.1 Relationship between TPH, the Company and Lisheng Pharmaceutical

As at the date of this announcement, TPH is the controlling shareholder of the Company holding 42.989% of the total shareholding in the Company, and TPH is also deemed to have an interest of approximately 50.93% in Lisheng Pharmaceutical. As such, Lisheng Pharmaceutical is regarded as an interested person of the Company for the purposes of Chapter 9 of the Listing Manual.

2.2 Information on Lisheng Pharmaceutical

Name of company	: Tianjin Lisheng Pharmaceutical Co. Ltd. (天津力生制药股份有限公司)
Domicile	: No. 16, Saida North 1 st Road, Xiqing Economic Development Zone, Tianjin (天津市西青经济开发区赛达北一道16号)
Uniform social credit No.	: 91120000103069502J
Type of company	: Joint stock company (股份有限公司)
Legal representative	: ZHANG Ping (张平)
Date of incorporation	: 17 June 1981
Registered capital	: RMB183,992,992
Business scope	: Production of tablets, hard capsule formulations, granules, drop pills, active pharmaceutical ingredients and plastic bottles, and

chemical raw materials (excluding hazardous, flammable, explosive, and controlled substances) (the aforementioned items are operated by branches only); general freight transportation; leasing of self-owned equipment and self-owned properties; export of products manufactured by the company itself and import of machinery, equipment, spare parts, and raw materials required by the company (excluding items restricted or prohibited by national regulations on import and export of goods and technologies); purchase of agricultural products (subject to industry permits, operated with valid licenses, and in compliance with special regulations specified by the state); production and sales of health supplements, retail and wholesale of edible agricultural products, food production, production, wholesale and retail of cosmetics, sales of daily goods, production and sales of sanitary products and disposable medical supplies, technical services, technical development, technical consulting, technical exchange, technology transfer, technology promotion, pharmaceutical import and export, technology import and export, pharmaceutical contract manufacturing, manufacture of medical packaging materials, sales of packaging materials and products, information consulting services (excluding licensed information consulting services), enterprise management consulting, market marketing planning, market research (excluding foreign-related research), internet sales (excluding products requiring permits), health consulting services (excluding medical diagnosis and treatment), conference and exhibition services, labour services (excluding labour dispatch), advertising production, advertising publication (excluding broadcasting stations, TV stations, newspaper and periodical publishing units), advertising design, agency services; general goods warehousing services (excluding for hazardous chemicals and other items subject to license approval), manufacturing and sales of experimental and analytical instruments, wholesale and retail of computer hardware and software and auxiliary equipment, manufacturing and repair of instruments and meters (where any of the above items are subject to industry license, the business activities shall be carried out with such license within its validity period, and for items subject to special regulations, the business activities shall be carried out in accordance with such special regulations).

3. THE PROPOSED ACQUISITION

3.1 Information on TPGF

Name of company	:	Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司)
Date of incorporation	:	14 September 2016
Uniform social credit No.	:	91120118MA05L0R67F
Type of company	:	Limited liability company (有限责任公司)

Business address : 3-2-501/502 & 3-3-501 Ronghe Square, No. 168 Fourth West Road, Tianjin Airport Economic Zone (天津自贸试验区 (空港经济区) 西四道 168 号融合广场 3-2-501、502; 3-3-501)

Legal representative : XING Jianhua (幸建华)

Registered capital : RMB500,000,000

Business scope : Absorbing deposits from the member entities of TPH, its subsidiaries and associated companies (collectively, the “**TPH Group**”) (吸收成员单位存款); handling loans for the member entities of the TPH Group (办理成员单位贷款); handling discounting of negotiable instruments for the member entities of the TPH Group (办理成员单位票据贴现); handling fund settlement, receipt and payment for the member entities of the TPH Group (办理成员单位资金结算与收付); providing entrusted loans, bond underwriting, non-financial letter of guarantee, financing consulting, credit authentication and related consulting and agency services⁴ to member entities of the TPH Group (提供成员单位委托贷款、债券承销、非融资性保函、财务顾问、信用鉴证及咨询代理业务); engaging in inter-bank borrowings (从事同业拆借); handling acceptance of negotiable instruments for the member entities of the TPH Group (办理成员单位票据承兑); and engaging in securities (other than shares/stocks) investment (除股票投资以外类有价证券投资)

3.2 Shareholding structure of TPGF

As at the date of this announcement, the shareholdings in TPGF are in the following proportions:

No.	Name of shareholders	Equity Contribution (RMB)	Shareholding Proportion
1.	TPH	250,000,000	50%
2.	The Company	75,000,000	15%
3.	Lisheng Pharmaceutical	75,000,000	15%
4.	Tianjin Yaoye Group Co., Ltd. (天津药业集团有限公司)	75,000,000	15%
5.	Tianjin Jin Yi Investment Guarantee Co., Ltd. (天津金益投资担保有限责任公司)	25,000,000	5%
Total		500,000,000	100%

Note: The Sale Equity is not subject to any mortgage, pledge or transfer restrictions. There are no ongoing legal disputes, arbitration matters, or judicial measures such as seizure or freeze affecting the ownership status of the Sale Equity. There are no other circumstances restricting the transfer of ownership of the Sale Equity.

3.3 Key financials of TPGF

Items	As at 30 December 2022 (audited)	As at 31 March 2023 (audited)	As at 31 August 2023 (unaudited)
Total assets	RMB2,984,440,900	RMB3,246,978,500	RMB3,907,052,500
Total liabilities	RMB2,399,529,300	RMB2,661,670,700	RMB3,313,687,400
Net assets	RMB584,911,600	RMB585,307,800	RMB593,365,100
Items	2022	January to March 2023	January to August 2023
Revenue	RMB45,900,600	RMB12,228,600	RMB34,956,600
Operating Profit	RMB28,087,700	RMB606,000	RMB15,987,400
Total profit	RMB28,087,700	RMB606,000	RMB15,987,400
Net profit	RMB21,109,300	RMB396,200	RMB11,953,500

Based on the audited financial statements of TPGF as at 31 March 2023 and the unaudited financial statements of TPGF as at 31 August 2023, the book value of the Sale Equity is approximately RMB87,796,170 and RMB89,004,765 respectively.

3.4 Valuation of TPGF

According to the valuation report (Huaya Zhengxin Appraisal Report No. [2023] A05-0007) (the “**Valuation Report**”) dated 15 June 2023 issued by Beijing Huaya Zhengxin Asset Appraisal Co., Ltd. (北京华亚正信资产评估有限公司) with 31 March 2023 as the valuation benchmark date, as disclosed by Lisheng Pharmaceutical, the summary of valuation of TPGF is as follows:

Summary of valuation (asset-based approach)

Items	Book value	Appraised value	Whether Increase or decrease	Rate of increase
Total assets	RMB3,246,978,500	RMB3,247,163,100	RMB184,600	0.0057%
Total liabilities	RMB2,661,670,700	RMB2,661,670,700	-	-
Net assets	RMB585,307,800	RMB585,492,400	RMB184,600	0.0300%

Based on the Valuation Report, the appraised value of the Sale Equity is approximately RMB87,823,860 and the NTA value of the Sale Equity is approximately RMB87,410,610.

3.5 The transaction price for the Sale Equity

Lisheng Pharmaceutical initiated the public listing-for-sale process on the TPRE to solicit potential transferees for the Sale Equity in accordance with the relevant requirements governing the transfer of state-owned assets of enterprise in the PRC at the Initial Bidding Price. The successful bidder will be determined in accordance with the bidding process, and the final transaction price for the Sale Equity will be based on the final bidding price to be offered by the successful bidder in the public listing-for-sale process.

4. THE EQUITY TRANSFER AGREEMENT

The salient terms of the equity transfer agreement (the “**Equity Transfer Agreement**”) are set out below.

- 4.1 The transferee shall pay an amount of RMB26 million to an account designated by the TPPE in accordance with the requirements of the transferor and the TPPE as security for the transferee’s intention to acquire the Sale Equity prior to the execution of the Equity Transfer Agreement and for the purposes of demonstrating the credit status and performance capability of the transferee.
- 4.2 Following the completion of the valuation of the Sale Equity, the transferor shall commence the public listing-for-sale process on the TPPE to solicit potential transferees for the Sale Equity. The transferee and transfer price shall be determined through either an agreement or an online bidding process, and the Equity Transfer Agreement shall be entered into between the transferor and the successful bidder.
- 4.3 The transfer of the Sale Equity does not involve land leasing, personnel placement or horizontal competition etc.
- 4.4 Following the transfer of the Sale Equity, TPGF shall continue to bear and enjoy the debts and creditor’s rights towards creditors and debtors.
- 4.5 During the period from the transaction benchmark date to the completion of the transfer of the Sale Equity, any profits or losses of the Sale Equity shall be fully enjoyed or borne by the transferee.
- 4.6 The industrial and commercial modification registration formalities for the Sale Equity shall only be carried out upon (i) the approval from Tianjin Regulatory Bureau of the National Administration of Financial Regulation (国家金融监督管理总局天津监管局) for the shareholder qualification of the transferee in TPGF being obtained by the transferee and (ii) the requirements under the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (including obtaining shareholders’ approval at the general meeting of Tianjin Development Holdings Limited (“**Tianjin Development**”), the indirect controlling shareholder of Lisheng Pharmaceutical, for the transfer of the Sale Equity and all transactions arising therefrom (if applicable)) being met by Tianjin Development.

5. RELATIVE FIGURES UNDER RULE 1006 OF THE LISTING MANUAL

Based on the unaudited financial statements of the Group for the financial period ended 30 June 2023 (being the latest announced consolidated financial statements of the Group) and the unaudited financial statements of TPGF for the corresponding financial period, the relative figures in respect of the Proposed Acquisition computed on the bases set out in Rule 1006 of the Listing Manual are as follows:

Rule	Bases of Computation	Relative Figures (%)
Rule 1006(a)	The net asset value of the assets to be disposed of, compared with the group's net asset value. This basis is not applicable to an acquisition of assets	Not applicable ⁽¹⁾

Rule 1006(b)	The net profits ⁽²⁾ attributable to the assets acquired or disposed of, compared with the group's net profits	1.20% ⁽³⁾
Rule 1006(c)	The aggregate value of the consideration given or received, compared with the issuer's market capitalisation ⁽⁴⁾ based on the total number of issued shares excluding treasury shares	0.40% ⁽⁵⁾
Rule 1006(d)	The number of equity securities issued by the issuer as consideration for an acquisition, compared with the number of equity securities previously in issue	Not applicable ⁽⁶⁾
Rule 1006(e)	The aggregate volume or amount of proved and probable reserves to be disposed of, compared with the aggregate of the group's proved and probable reserves. This basis is applicable to a disposal of mineral, oil or gas assets by a mineral, oil and gas company, but not to an acquisition of such assets. If the reserves are not directly comparable, the Exchange may permit valuations to be used instead of volume or amount	Not applicable ⁽⁷⁾

Notes:

- (1) This basis is not applicable as the Proposed Acquisition is not a disposal of assets.
- (2) Under Rule 1002(3)(b) of the Listing Manual, "net profits" means profit or loss including discontinued operations that have not been disposed and before income tax and non-controlling interests. Under Rule 1002(3)(c) of the Listing Manual, the net asset and net profit figures used for comparison with the transaction(s) under consideration will be taken from the latest announced consolidated accounts. The SGX-ST may allow the issuer's net asset value or net profit to be adjusted to take into account any transaction(s) completed subsequent to the latest announced consolidated accounts provided that adequate information about such transaction(s) has already been announced to shareholders.
- (3) The relative figure computed on the basis under Rule 1006(b) of the Listing Manual is determined by dividing the net profits attributable to the Sale Equity of approximately RMB8,550,100 for the six (6) months ended 30 June 2023 by the Group's unaudited net profit of approximately RMB714,467,000 for the six (6) months ended 30 June 2023.
- (4) Under Rule 1002(5) of the Listing Manual, "market capitalisation" is determined by multiplying the number of shares in issue by the weighted average price of such shares transacted on the market day preceding the date of the sale and purchase agreement.
- (5) Based on the Initial Bidding Price (i.e., RMB87,823,860) and the market capitalisation of the Company of approximately RMB21,721,952,535.36 (determined by multiplying the 570,250,076 shares of the Company in issue and traded on the Shanghai Stock Exchange (the "A-Shares") by the volume-weighted average price of the A-Shares of RMB33.36 and 200,000,000 shares of the Company in issue and traded on the SGX-ST (the "S-Shares", together with the A-Shares, the "Shares") by the volume-weighted average price of the S-Shares of USD1.87 (exchange rate: USD1:RMB7.215) on 8 September 2023 (being the immediate market day preceding the date of this announcement). For the avoidance of doubt, in view that the Proposed Acquisition is through a public listing-for-sale (公开挂牌转让) process, and the Equity Transfer Agreement will only be entered into

between the parties following the Company has become the successful bidder. As at the date of this announcement, there is no certainty or assurance that the Company will become the successful bidder. As such, for the purposes of this announcement, the market capitalisation of the Company has been determined by multiplying the number of shares in issue by the weighted average price of such shares transacted on the market day preceding the date of this announcement.

- (6) This basis is not applicable as no equity securities will be issued by the Company as consideration for the Proposed Acquisition.
- (7) This basis is not applicable as the Company is not a mineral, oil and gas company.

As the relative figures computed under Rules 1006(b) and 1006(c) of the Listing Manual do not exceed 5%, the Proposed Acquisition constitutes a “non-discloseable transaction” pursuant to Rule 1008 of the Listing Manual.

6. CHAPTER 9 OF THE LISTING MANUAL

- 6.1 Rule 905(1) of the Listing Manual provides that an issuer must make an immediate announcement of any interested person transaction (as defined in the Listing Manual) of a value equal to, or more than, 3% of the group's latest audited NTA, and Rule 905(2) provides that if the aggregate value of all transactions entered into with the same interested person (as defined in the Listing Manual) during the same financial year amounts to 3% or more of the group's latest audited NTA, the issuer must make an immediate announcement of the latest transaction and all future transactions entered into with that same interested person during that financial year. Pursuant to Rule 905(3) of the Listing Manual, Rule 905(1) and (2) do not apply to any transaction below S\$100,000.
- 6.2 As disclosed in paragraph 1.2 of this announcement, as at the date of this announcement, the Company's controlling shareholder, TPH is deemed to have an interest of approximately 50.93% in Lisheng Pharmaceutical. Accordingly, Lisheng Pharmaceutical is an associate (as defined under the Listing Manual) of TPH and therefore, Lisheng Pharmaceutical is regarded as an interested person of the Company for the purposes of Chapter 9 of the Listing Manual, and the Proposed Acquisition constitutes an interested person transaction under the Listing Manual.

As disclosed in paragraph 1.1 of this announcement, the Initial Bidding Price of RMB87,823,860, being the amount at risk to the Company, represents approximately 1.35% of the Group's latest audited NTA of RMB6,493,593,000 as at 31 December 2022 which is less than 3% and accordingly, the Proposed Acquisition is an interested person transaction which is not subject to the disclosure requirements under Chapter 9 of the Listing Manual. Shareholders and/or potential investors should note that, as disclosed in paragraph 1.1 of this announcement, if a competitive bidding process occurs, the final transaction price for the Sale Equity will be determined based on the bidding results. The Company will keep shareholders updated on any material developments in relation to the Proposed Acquisition by way of announcements as and when appropriate.

For the current financial year beginning 1 January 2023 up to the date of this announcement (the “**Relevant Period**”), save for the Proposed Acquisition, there are no other interested person transactions (excluding transactions less than S\$100,000) that were or are proposed to be entered into by the Company with Lisheng Pharmaceutical.

Further, save for transaction(s) which has been approved by shareholders of the Company, or is the subject of aggregation with another transaction that has been approved by shareholders of the Company, there are no interested person transactions (excluding transactions less than

S\$100,000) entered into by the Company, its subsidiaries and/or associated companies, which are considered to be an “entity at risk” within the meaning of Rule 904(2) of the Listing Manual with TPH and/or its associates (as defined under the Listing Manual) for the Relevant Period.

7. RATIONALE FOR, AND IMPACT OF, THE PROPOSED ACQUISITION

As a non-bank financial institution approved by the China Banking and Insurance Regulatory Commission (中国银行保险监督管理委员会), TPGF was established to provide financial services under its business scope including, amongst others, settlement and intermediary business services, deposit business services and credit business services to the member entities in the TPH Group (including the Company). TPGF exhibits stable profitability and provides financial services to the member entities of the TPH Group, and its asset impairment risk is relatively low; TPGF provides loan services to the Company and its controlled subsidiaries (as determined in accordance with the laws of the PRC) and provides financial support and a streamlined financing channel for the Company's long-term development. This helps satisfy the Company's demand to lower financing costs while developing its own business. By providing deposit services to the Company and its controlled subsidiaries (as determined in accordance with the laws of the PRC), which contributes to optimising the Company's financial management and improving the efficiency of fund utilisation. Acting as a fund settlement platform, TPGF facilitates convenient and efficient settlement between the Company, TPH and other affiliated enterprises, reducing the transit time of funds and accelerating fund turnover. TPGF's performance has growth potential, and with the rapid growth of enterprises within the TPH Group, TPGF's earnings are expected to increase, which would provide better returns for its shareholders.

The Proposed Acquisition would not be detrimental to the interests of the Company and its minority shareholders and will not affect the Company's independence.

8. DECISION-MAKING PROCESS FOR THE PROPOSED ACQUISITION

8.1 Board meeting

On 11 September 2023, the Company duly convened its FY2023 6th Board Meeting, and the Board considered and approved the Proposed Acquisition. The Interested Directors have abstained from voting at the said Board meeting in respect of the resolution approving the Proposed Acquisition, and the remaining six (6) directors (including all three (3) Independent Directors) have approved the Proposed Acquisition.

8.2 Opinions from the independent directors

In accordance with relevant laws and regulations including the *Listing Rules of the Shanghai Stock Exchange* (《上海证券交易所股票上市规则》), the Independent Directors have given their opinions on the Proposed Acquisition as follows:

- (a) the convening and voting procedures of the FY2023 6th Board Meeting comply with relevant laws and regulations, as well as the Articles of Association of the Company, and the Interested Directors have abstained from voting on the resolution approving the Proposed Acquisition;
- (b) the Proposed Acquisition adheres to the principles of equality, free will and mutual benefit, and neither affects the independence of the Company nor the interests of the Company and its minority shareholders; and

- (c) the contents of the Equity Transfer Agreement are legal and valid, and not in violation of any mandatory provisions of laws, regulations and normative documents which are currently in force.

9. PREVIOUS TRANSACTIONS

In accordance with the PRC laws including the listing rules of the Shanghai Stock Exchange, save for (i) the transactions entered into by the Company with TPH Group relating to labour services and house leasing with an aggregate value of approximately RMB39,275,900, representing 0.60% of the Company's latest audited net assets attributable to its parent company, and (ii) the subscription of shares in NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司), a controlled subsidiary (as determined in accordance with the laws of the PRC) of the Company and a joint investment¹ with TPH, with an aggregate value of RMB96,000,000, representing 1.47% of the Company's latest audited net assets attributable to its parent company, there were no other related party transactions (excluding transactions conducted under the general shareholders' mandate) over the past 12 months immediately preceding the date of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution in trading the shares in the Company as there is no certainty or assurance as at the date of this announcement that the Company will become the successful bidder, and the Equity Transfer Agreement will be entered into, or the Proposed Acquisition will be undertaken or completed at all.

Shareholders and potential investors are advised to read this announcement and any further announcement(s) by the Company carefully and to refrain from taking any action in respect of their shares in the Company which may be prejudicial to their interests. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
11 September 2023

¹ As at the date of this announcement, TPH holds 1.94% of the total shareholding in NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司).